1-14 of 14
Daisy Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Free
Moshe Levy, David Andorsky, CelesteAnn Bremer, Joshua Zeidner, Neil Palmisiano, Steven McCune, Anthony Hunter, Zohra Nooruddin, Haifaa Abdulhaq, Vivian Oehler, Shaker Dakhil, Brian Mulherin, Gustavo Fonseca, Michael Heinrich, Omer Jamy, Paul Koller, Koji Sasaki, Islam Mohamad Sadek, Daisy Yang, Dramane Laine, John (randy) Sabo, Amanda Hall, Dheeraj Gianchandani, Michael Mauro, Jorge Cortes, Ehab Atallah
Journal: Blood
Blood (2025) 146 (Supplement 1): 3775.
https://doi.org/10.1182/blood-2025-3775
Published: 2025
Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Free
Jorge Cortes, Ehab Atallah, David Andorsky, Marlise Luskin, Srinivas Tantravahi, Koji Sasaki, James Dugan, CelesteAnn Bremer, Vivian Oehler, Joshua Zeidner, Moshe Levy, Camille Abboud, Paul Koller, Bonnie Kiner-Strachan, Habte Yimer, Islam Mohamad Sadek, Daisy Yang, Dramane Laine, John (randy) Sabo, Bridget Cooper, Ennan Gu, Michael Mauro
Journal: Blood
Blood (2025) 146 (Supplement 1): 906.
https://doi.org/10.1182/blood-2025-906
Published: 2025
Journal Articles

Real-world analysis of asciminib as first-line therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A chart review Study in the United States

Free
Ehab Atallah, Islam Mohamad Sadek, Emily McGovern, Dominick Latremouille-Viau, Carmine Rossi, Remi Bellefleur, Gabriel Marquez, Annie Guerin, Daisy Yang, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 8178.
https://doi.org/10.1182/blood-2025-8178
Published: 2025
Journal Articles

The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)

Free
Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Mohamad Sadek, Annie Guerin, Kathryn Flynn
Journal: Blood
Blood (2025) 146 (Supplement 1): 6388.
https://doi.org/10.1182/blood-2025-6388
Published: 2025
Journal Articles

A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase

Free
Ehab Atallah, Islam Mohamad Sadek, Emily McGovern, Dominick Latremouille-Viau, Carmine Rossi, Remi Bellefleur, Nathan Gobeil, Gabriel Marquez, Annie Guerin, Daisy Yang, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 724.
https://doi.org/10.1182/blood-2025-724
Published: 2025
Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Free
Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 3812.
https://doi.org/10.1182/blood-2024-193201
Published: 2024
Journal Articles

ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs

Free
Anchit Khanna, Hannah Small, Dhamend Lutchman, Rafael Erlich, Gabriel Marquez, Daisy Yang, Kejal Jadhav
Journal: Blood
Blood (2024) 144 (Supplement 1): 4527.
https://doi.org/10.1182/blood-2024-201022
Published: 2024
Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Free
Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota
Journal: Blood
Blood (2024) 144 (Supplement 1): 2434.
https://doi.org/10.1182/blood-2024-201831
Published: 2024
Journal Articles

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Free
Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Courtney McDermott, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn E. Flynn
Journal: Blood
Blood (2024) 144 (Supplement 1): 7913.
https://doi.org/10.1182/blood-2024-207213
Published: 2024
Journal Articles

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Free
Gaurav Vadnerkar, Joan Clements, Mel Mann, Vainavika Reddy Gaddam, Chaitali Nag, Shiva Padhi, David Wei, Marcello Azolino, Kejal Jadhav, Daisy Yang, Andrea Damon, Islam Sadek
Journal: Blood
Blood (2024) 144 (Supplement 1): 5192.
https://doi.org/10.1182/blood-2024-199951
Published: 2024
Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Free
Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes
Journal: Blood
Blood (2024) 144 (Supplement 1): 479.
https://doi.org/10.1182/blood-2024-200717
Published: 2024
Journal Articles

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Free
Ehab L. Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul B. Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan GU, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6389.
https://doi.org/10.1182/blood-2023-186974
Published: 2023
Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Free
Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5098.
https://doi.org/10.1182/blood-2023-180772
Published: 2023
Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Free
Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav
Journal: Blood
Blood (2023) 142 (Supplement 1): 5190.
https://doi.org/10.1182/blood-2023-180789
Published: 2023